Legacy Capital Group California Inc. Purchases 384 Shares of Sanofi (NASDAQ:SNY)

Legacy Capital Group California Inc. raised its position in Sanofi (NASDAQ:SNY) by 4.7% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 8,495 shares of the company’s stock after acquiring an additional 384 shares during the period. Legacy Capital Group California Inc.’s holdings in Sanofi were worth $412,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Frazier Financial Advisors LLC acquired a new position in Sanofi during the fourth quarter valued at approximately $28,000. Larson Financial Group LLC raised its position in Sanofi by 480.8% during the first quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock worth $29,000 after acquiring an additional 500 shares in the last quarter. Register Financial Advisors LLC acquired a new stake in Sanofi in the first quarter valued at $29,000. McIlrath & Eck LLC grew its position in shares of Sanofi by 143.3% in the 4th quarter. McIlrath & Eck LLC now owns 613 shares of the company’s stock valued at $30,000 after acquiring an additional 361 shares during the period. Finally, Johnson Financial Group Inc. acquired a new position in shares of Sanofi during the 4th quarter worth about $31,000. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Stock Performance

SNY stock traded up $0.45 during mid-day trading on Wednesday, hitting $55.23. 1,706,693 shares of the company were exchanged, compared to its average volume of 2,108,165. Sanofi has a 1-year low of $42.63 and a 1-year high of $55.72. The stock has a market capitalization of $139.88 billion, a PE ratio of 27.60, a price-to-earnings-growth ratio of 1.56 and a beta of 0.59. The business has a 50 day simple moving average of $50.53 and a 200-day simple moving average of $48.92. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.05. The business had revenue of $10.75 billion during the quarter, compared to analysts’ expectations of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period last year, the firm posted $0.95 EPS. On average, equities analysts forecast that Sanofi will post 4.19 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on SNY. Argus lifted their price target on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, July 26th. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a report on Sunday. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.